RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics
IKT•Form 3 filing reports 25 million shares
RA Capital Management filed a Form 3 showing beneficial ownership of 25 million Inhibikase Therapeutics common shares.
The filing lists RA Capital as a 10% owner, with the position reported as indirect ownership.
The event date was July 10, 2026; the statement was signed and dated July 17, 2026.
